Table 3.
The pharmacokinetic parameters of PF403 (as the metabolite) in rats after oral administration (n = 6).
| Parameters | CAT3 | OA-CAT3 | CAT3-SLN | OA-CAT3-SLN | |
|---|---|---|---|---|---|
| AUC(0–t) | ng·mL−1·h | 18.778 ± 1.953 * | 13.713 ± 5.616 * | 21.723 ± 6.763 * | 32.045 ± 7.425 |
| AUC(0–∞) | ng·mL−1·h | 24.42 ± 2.435 * | 30.861 ± 24.886 | 25.541 ± 9.898 * | 34.73 ± 6.178 |
| MRT(0–t) | H | 9.775 ± 0.104 | 9.677 ± 1.252 | 6.649 ± 1.068 | 5.945 ± 0.889 |
| MRT(0–∞) | H | 16.449 ± 0.87 | 56.077 ± 75.093 | 10.837 ± 4.978 | 7.742 ± 1.978 |
| t 1/2z | H | 10.121 ± 0.759 | 39.049 ± 53.163 | 8.94 ± 3.181 | 6.218 ± 1.528 |
| T max | H | 8 ± 0 | 4.736 ± 3.834 | 0.264 ± 0.123 | 0.417 ± 0.129 |
| Vz/F | L/kg | 6011.79 ± 535.387 | 15,412.451 ± 13,804.038 | 5298.387 ± 1424.022 | 2807.484 ± 748.904 |
| CLz/F | L/h/kg | 412.919 ± 41.283 | 442.039 ± 193.353 | 439.687 ± 152.452 | 333.068 ± 131.27 |
| C max | ng/mL | 1.429 ± 0.171 ** | 1.431 ± 0.315 ** | 7.884 ± 1.621 | 7.36 ± 1.694 |
* p < 0.05, ** p < 0.01 versus OA-CAT3-SLN.